TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2741191

Group type: EXPERIMENTAL
Intervention: Clindamycin 900 mg every 8 h admixed with gentamicin 1.5 mg/kg every 8 h (8-h group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Clindamycin 600 mg every 6 h given separately (6-h group)
Number of subjects: 21
Study: 31567873

Group type: EXPERIMENTAL
Intervention: 50 mg/d PhytoSERM for 12 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 100 mg/d PhytoSERM
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30636738

Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day as adjunctive therapy
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day as adjunctive therapy with memantine
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/day with memantine
Number of subjects: 1463
Study: 28712618

Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1119
Study: 25316259

Group type: EXPERIMENTAL
Intervention: S‐1 plus oxaliplatin (SOX)
Number of subjects: 685

Group type: COMPARATOR
Intervention: Cisplatin plus S‐1 (CS)
Number of subjects: 685
Study: 23352231

Group type: EXPERIMENTAL
Intervention: Dehydration-Alcohol (DA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dehydration-Placebo (DP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Partial Rehydration-Alcohol (PA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Full Rehydration-Alcohol (FA)
Number of subjects: 16
Study: 21255982

Group type: EXPERIMENTAL
Intervention: Haloperidol, mean dosage 4.14 mg (±1.70), duration 42.92 days (±16.85)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Risperidone, mean dosage 4.17 mg (±1.55), duration 42.92 days (±16.85)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Early response (≥ 30% improvement in PANSS total score by week 2)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: PANSS positive subscore at admission
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Duration of untreated psychosis
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: PANSS general psychopathology subscore
Number of subjects: 112
Study: 19150366

Group type: EXPERIMENTAL
Intervention: Group-based counselling (A)
Number of subjects: 1948

Group type: COMPARATOR
Intervention: Referred care (B)
Number of subjects: 1948

Group type: COMPARATOR
Intervention: Low risk individuals
Number of subjects: 1948
Study: 17717252

Group type: EXPERIMENTAL
Intervention: CPAP (7.5 cm H2O)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (ambient pressure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 14672358

Group type: EXPERIMENTAL
Intervention: Exercise in a lower body negative pressure (LBNP) chamber (EX/LBNP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary control (SED)
Number of subjects: 16
Study: 11180021

Group type: EXPERIMENTAL
Intervention: 1.0 g of mycophenolate mofetil alone (study 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.0 g of mycophenolate mofetil and 2 tablets of iron ion preparations (study 2)
Number of subjects: 0
Study: 9195264

Group type: EXPERIMENTAL
Intervention: Supplementary nutrition (average intake of 2098 kcal/day for a total of 11 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (32 amputees in another hospital)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Supplementary nutrition group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 8479123

Group type: EXPERIMENTAL
Intervention: Gianturco self-expanding stent placed after percutaneous transvenous angioplasty (PTVA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no stent placed after PTA)
Number of subjects: 58
Study: 3100007

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem (all doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg (challenge after treatment)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem (sustained therapy)
Number of subjects: 15
Study: 29369963

Group type: EXPERIMENTAL
Intervention: Telephone-Basic Life Support (T-BLS) training program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard Basic Life Support (S-BLS) training program
Number of subjects: 24
Study: 27160475

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin (10.8 mg goserelin by subcutaneous injection on the first day of irradiation and 3 months later)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Radiotherapy alone (66 Gy in 33 fractions 5 days a week for 7 weeks)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin
Number of subjects: 743

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 743
Study: 24428904

Group type: EXPERIMENTAL
Intervention: Consultation support
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Consultation-plus-coaching support
Number of subjects: 3906

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3906
Study: 22420772

Group type: EXPERIMENTAL
Intervention: Cumulative sum charts
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual teaching (Control)
Number of subjects: 82
Study: 19966043

Group type: EXPERIMENTAL
Intervention: Intensive smoking-cessation intervention (5 counseling sessions + nicotine replacement)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 56
Study: 17990049

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (one patient received just 5 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 15777141

Group type: EXPERIMENTAL
Intervention: Inpatient psychiatric review followed by telephone case conferencing between specialist hospital staff and GPs to provide patient‐specific information about the patient's depression and its management, educational material, and ongoing clinical support.
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Brief phone advice from a psychiatrist (post hoc analysis).
Number of subjects: 669
Study: 12357142

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 10621763

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 8798934

Group type: EXPERIMENTAL
Intervention: Equipoise among patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical equipoise
Number of subjects: 0
Study: 1752498

Group type: EXPERIMENTAL
Intervention: Concentrated 25% albumin infusion for the first 16 hours after surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Concentrated 25% albumin infusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard crystalloid solution
Number of subjects: 28
Study: 7043498

Group type: EXPERIMENTAL
Intervention: Pimozide (40‐60 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol (40‐60 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 30612875

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5%/70% alcohol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Iodine 1%/70% alcohol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5%/70% alcohol and Iodine 1%/70% alcohol
Number of subjects: 49
Study: 29411890

Group type: EXPERIMENTAL
Intervention: Tailored breastfeeding support including a dedicated breastfeeding support worker, personalized capacity-building approach, and a low-stimuli environment for 5 days.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard Baby-Friendly Initiative care only.
Number of subjects: 14
Study: 26845265

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 482

Group type: COMPARATOR
Intervention: Lithium and Quetiapine (both with adjunctive personalized treatments)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Employed participants
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Greater improvement in functioning and quality of life
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Early (8 weeks) and very early (4 weeks) clinical changes in mood symptoms
Number of subjects: 482
Study: 24928472

Group type: EXPERIMENTAL
Intervention: Serum under‐O‐glycosylated IgA1 levels measured by HAA-ELISA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serum under‐O‐glycosylated polymeric IgA1 (pIgA1) measured by pIgA1 trap
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation between Area‐IgA and data from HAA‐ELISA or pIgA1 trap
Number of subjects: 32
Study: 21840117

Group type: EXPERIMENTAL
Intervention: 2-year screening interval (Gothenburg)
Number of subjects: 17503

Group type: COMPARATOR
Intervention: 4-year screening interval (Rotterdam)
Number of subjects: 17503
Study: 19896635

Group type: EXPERIMENTAL
Intervention: Standard-fluence PDT (50 J/cm²)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-fluence PDT (25 J/cm²)
Number of subjects: 42
Study: 17698900

Group type: EXPERIMENTAL
Intervention: vildagliptin (100 mg) with glibenclamide (5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: vildagliptin (100 mg) without glibenclamide (5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: glibenclamide (5 mg)
Number of subjects: 16
Study: 15449048

Group type: EXPERIMENTAL
Intervention: 123I‐MIBG intervention
Number of subjects: 39
Study: 12609779

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus transplantation of non-cultured melanocytes and keratinocytes (KM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus transplantation of cultured melanocytes (CC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Only cryotherapeutic treatment (OC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cryotherapy plus melanocyte culture medium (CM)
Number of subjects: 11
Study: 10588768

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) and praziquantel (40 mg/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole and praziquantel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8941458

Group type: EXPERIMENTAL
Intervention: Two-injection scheme (regimen A)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination of glibenclamide with one injection of NPH insulin at bedtime (regimen B)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination of glibenclamide with one injection of NPH insulin before breakfast (regimen C)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall insulin treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Combined insulin-sulfonylurea treatment
Number of subjects: 95
Study: 1949134

Group type: EXPERIMENTAL
Intervention: Recombinant sporozoite vaccine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6119926

Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate (DPCA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Diazepam (DP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 31706917

Group type: EXPERIMENTAL
Intervention: 12-week multicomponent frailty prevention program (exercise, cognitive training, board game activities)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 12-week multicomponent frailty prevention program
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 127
Study: 31140114

Group type: EXPERIMENTAL
Intervention: Ticagrelor pediatric tablets taken whole
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ticagrelor pediatric tablets suspended in water
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ticagrelor pediatric tablets and granules for oral suspension
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ticagrelor and its active metabolite AR‐C124910XX
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 44
Study: 27552823

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal boys)
Number of subjects: 60
Study: 25730133

Group type: EXPERIMENTAL
Intervention: <10th percentile group
Number of subjects: 0

Group type: COMPARATOR
Intervention: ≥10th percentile group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Customized birth weight percentile
Number of subjects: 0
Study: 23646469

Group type: EXPERIMENTAL
Intervention: Qingyang Toujie Mixture (QTM) in combination with prednisone tablet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo in combination with prednisone tablet
Number of subjects: 42
Study: 21123443

Group type: EXPERIMENTAL
Intervention: CR (25% calorie restriction)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CR+EX (12.5% CR plus 12.5% increase in energy expenditure by exercise)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (energy intake at 100% of energy requirements)
Number of subjects: 46
Study: 19180891

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment with density 1 settings
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment with density 2 settings
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment with density 3 settings
Number of subjects: 15
Study: 17419458

Group type: EXPERIMENTAL
Intervention: Cardioversion management principles; specific details on dosage and duration not available.
Number of subjects: 0
Study: 10960627

Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate/10 microg ethinyl E2
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate/5 microg ethinyl E2
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: 0.2 mg norethindrone acetate/1 microg ethinyl E2, 0.5 mg norethindrone acetate/2.5 microg ethinyl E2, 1 mg norethindrone acetate/5 microg ethinyl E2
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 8994456

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1638587

Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg once daily (or 20 mg/kg once daily) for 5 to 10 days
Number of subjects: 598

Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times daily (or 20 mg/kg daily in three equal doses) for 5 to 10 days
Number of subjects: 598
Study: 6143736

Group type: EXPERIMENTAL
Intervention: 15 mg propranolol i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.5 mg mepindolol sulfate i.v.
Number of subjects: 6
Study: 30466891

Group type: EXPERIMENTAL
Intervention: Custirsen added to first-line chemotherapy with docetaxel
Number of subjects: 600
Study: 29267994

Group type: EXPERIMENTAL
Intervention: Automated devices, clinical training, and support for systems change
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison sites (control)
Number of subjects: 6
Study: 26746173

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Strain-Counterstrain (SCS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham SCS
Number of subjects: 34
Study: 24708193

Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 300

Group type: COMPARATOR
Intervention: US/chest radiography
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Routine PET/CT
Number of subjects: 300
Study: 22735317

Group type: EXPERIMENTAL
Intervention: Suture anchor
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transosseous suture
Number of subjects: 40
Study: 20426957

Group type: EXPERIMENTAL
Intervention: Guaifenesin compound pseudoephedrine hydrochloride oral solution
Number of subjects: 412

Group type: COMPARATOR
Intervention: Ambroxol hydrochloride oral solution
Number of subjects: 412
Study: 18036464

Group type: EXPERIMENTAL
Intervention: Upright positioning by a parent
Number of subjects: 118

Group type: COMPARATOR
Intervention: Lying flat on an exam table (Control)
Number of subjects: 118
Study: 16035979

Group type: EXPERIMENTAL
Intervention: Event recorder monitoring
Number of subjects: 310

Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 310
Study: 11932881

Group type: COMPARATOR
Intervention: Double-blind studies
Number of subjects: 28

Group type: COMPARATOR
Intervention: Studies with larger rates of withdrawal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trials with power calculations
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trials specifying outcomes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trials with sample size per arm
Number of subjects: 28
Study: 10404707

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lithium combined with Carbamazepine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Nonresponders at baseline
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Nonresponders during pharmacotherapy
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Moderately abnormal EEGs
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Small sharp spikes
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Microsleep
Number of subjects: 202
Study: 7551920

Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 day 1) + etoposide (100 mg/m2 days 1‐3) every 3 weeks (PE‐‐arm A)
Number of subjects: 393

Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 every 4 weeks) + mitomycin (8 mg/m2 days 1, 29, 71) + vindesine (3 mg/m2 days 1, 8, 15, 22 every 2 weeks) (MVP‐‐arm B)
Number of subjects: 393

Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 day 1) + mitomycin (6 mg/m2 day 1) + ifosfamide (3 g/m2 day 2) every 3 weeks (MIC‐‐arm C)
Number of subjects: 393
Study: 2403992

Group type: EXPERIMENTAL
Intervention: Hypnosis labeled relaxation exercise
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Relaxation labeled relaxation exercise
Number of subjects: 63

Group type: COMPARATOR
Intervention: Neutral tape (Control)
Number of subjects: 63
Study: 31173455

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 175
Study: 28732826

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler (GFF MDI) 2.4/9.6 mug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 mug
Number of subjects: 0
Study: 24870575

Group type: EXPERIMENTAL
Intervention: Brisk walking in cold (8°C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Brisk walking in neutral (20°C)
Number of subjects: 16
Study: 23391032

Group type: EXPERIMENTAL
Intervention: Enamel microabrasion alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combined approach (enamel microabrasion and in-office bleaching)
Number of subjects: 10
Study: 21664003

Group type: EXPERIMENTAL
Intervention: HEPA oxygen mask
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hudson-type mask
Number of subjects: 0
Study: 20078201

Group type: EXPERIMENTAL
Intervention: Mandibular symphysis bone grafting followed by postoperative orthodontic treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 75
Study: 17603326

Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) using radiofrequency technique
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tonsillectomy (TE) (blunt dissection)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both TT and TE groups
Number of subjects: 74
Study: 15838199

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (six sessions with safer sex information, interactive learning activities, and discussion groups facilitated by HIV-seropositive peers)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Standard intervention (one session providing safer sex information)
Number of subjects: 811
Study: 12457002

Group type: EXPERIMENTAL
Intervention: Budesonide Novolizer
Number of subjects: 315

Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler
Number of subjects: 315
Study: 9819039

Group type: EXPERIMENTAL
Intervention: rFVIIa (NovoSeven) administered at home
Number of subjects: 5

Group type: COMPARATOR
Intervention: In-hospital management of bleeding episodes
Number of subjects: 5
Study: 7648636

Group type: EXPERIMENTAL
Intervention: China-mode Hepatitis A attenuated live vaccine
Number of subjects: 62698

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 62698

Group type: EXPERIMENTAL
Intervention: Persons who missed vaccination in case group
Number of subjects: 62698

Group type: COMPARATOR
Intervention: Mistakenly vaccinated individuals in control group
Number of subjects: 62698

Group type: COMPARATOR
Intervention: External control group
Number of subjects: 62698
Study: 2516430

Group type: EXPERIMENTAL
Intervention: HuIFN-beta (1 or 3 million international units per day for 4 or 12 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HuIFN-beta
Number of subjects: 24

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 24
Study: 339935

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg three times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mianserin (10 mg three times a day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 20
Study: 30661847

Group type: EXPERIMENTAL
Intervention: Yoga-CaRe program (13 sessions supervised by an instructor and encouragement to self-practice daily)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Enhanced standard care (3 sessions of health education)
Number of subjects: 4000
Study: 29217503

Group type: EXPERIMENTAL
Intervention: PHR-based intervention group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 25832425

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, po)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24